|
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016 open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15 |
Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter
Copyright Infringement Claims
Indexing Partner
|
Published Paper Details
|
|
| Paper Title: | INTRANASAL VACCINE FOR COVID-19: iNCOVACC |
| Authors Name: | Archana Singh Yadav , Nishi Kumari |
| Unique Id: | IJSDR2304199 |
| Published In: | Volume 8 Issue 4, April-2023 |
| Abstract: | The corona virus disease 2019 (COVID-19), which is caused by infection with the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), has already claimed more than 6.8 million lives worldwide. Most COVID-19 vaccines target the spike protein of the ancestral SARS-CoV-2 strain. Due to the presence of numerous mutations on SARS-CoV-2 variant spike proteins, the efficacy of these vaccines has been significantly reduced. Therefore, scientists are looking to improve current vaccine formulations to provide better protection against SARS-CoV-2 infection. An effective intranasal vaccine could be extremely beneficial in managing the COVID-19 pandemic by eliciting both mucosal protective immunity at the site of infection and systemic immunity. India on the 74th Republic Day got its first intranasal COVID-19 vaccine iNCOVACC. On Thursday, Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh 2023 launched the first intranasal COVID-19 vaccine, developed by Bharat Biotech. Nasal vaccines can be more effective at preventing infections because the shots target the mucosal linings of the nasal airways, which is the point of entry for the coronavirus. By protecting these linings, the vaccine can block the infection and transmission of the virus in both the upper and lower respiratory tracts. There is no doubt that IN vaccines have their own set of potential advantages over the IM vaccine. IN vaccine is a promising preventive strategy for SARSCoV-2 considering the remarkable protective immunity in the mucosal sites. |
| Keywords: | COVID-19, SARS-CoV-2, VOCs, SIgA, NTAGI, NALT |
| Cite Article: | "INTRANASAL VACCINE FOR COVID-19: iNCOVACC", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.8, Issue 4, page no.1234 - 1237, April-2023, Available :http://www.ijsdr.org/papers/IJSDR2304199.pdf |
| Downloads: | 000337212 |
| Publication Details: | Published Paper ID: IJSDR2304199 Registration ID:205322 Published In: Volume 8 Issue 4, April-2023 DOI (Digital Object Identifier): Page No: 1234 - 1237 Publisher: IJSDR | www.ijsdr.org ISSN Number: 2455-2631 |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijsdr.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
Track Paper
Important Links
Conference Proposal
ISSN
 |
 |
DOI (A digital object identifier)
  Providing A digital object identifier by DOI How to GET DOI and Hard Copy Related |
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
 |
 |
 |
Social Media
Indexing Partner |
|||
| Copyright © 2024 - All Rights Reserved - IJSDR | |||
Facebook Twitter Instagram LinkedIn